Pharmacotherapy for Nonalcoholic Fatty Liver Disease

Research output: Contribution to journalArticle

21 Scopus citations


Lifestyle modifications and optimization of the management of cardiometabolic comorbidities are currently the mainstay of treatment for patients with nonalcoholic fatty liver disease. Pharmacotherapy to halt or reverse hepatic histological injury and prevent the development of end-stage liver disease is specifically offered to patients with nonalcoholic steatohepatitis (NASH) and those with advanced fibrosis. In this review, the authors discuss the state of the art of various pharmacological agents for NASH. The efficacy of vitamin E and pioglitazone is reasonably well established in a selected group of patients with NASH. Current data do not offer convincing evidence for efficacy of pentoxifylline, long-chain polyunsaturated fatty acids, angiotensin receptor blockers, metformin, or ursodeoxycholic acid. They also discuss the state of several emerging agents for treating NASH including the farsenoid X receptor ligand, obeticholic acid.

Original languageEnglish (US)
Pages (from-to)338-348
Number of pages11
JournalSeminars in Liver Disease
Issue number3
StatePublished - Aug 20 2015


  • nonalcoholic fatty liver disease
  • nonalcoholic steatohepatitis
  • obeticholic acid
  • thiazolidinedione
  • Vitamin E

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Pharmacotherapy for Nonalcoholic Fatty Liver Disease'. Together they form a unique fingerprint.

  • Cite this